1. Home
  2. LQDA vs EVEX Comparison

LQDA vs EVEX Comparison

Compare LQDA & EVEX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LQDA
  • EVEX
  • Stock Information
  • Founded
  • LQDA 2004
  • EVEX 2020
  • Country
  • LQDA United States
  • EVEX United States
  • Employees
  • LQDA N/A
  • EVEX N/A
  • Industry
  • LQDA Biotechnology: Pharmaceutical Preparations
  • EVEX Aerospace
  • Sector
  • LQDA Health Care
  • EVEX Industrials
  • Exchange
  • LQDA Nasdaq
  • EVEX Nasdaq
  • Market Cap
  • LQDA 1.4B
  • EVEX 1.3B
  • IPO Year
  • LQDA 2018
  • EVEX N/A
  • Fundamental
  • Price
  • LQDA $14.92
  • EVEX $5.41
  • Analyst Decision
  • LQDA Strong Buy
  • EVEX Strong Buy
  • Analyst Count
  • LQDA 8
  • EVEX 3
  • Target Price
  • LQDA $27.13
  • EVEX $6.00
  • AVG Volume (30 Days)
  • LQDA 2.1M
  • EVEX 210.7K
  • Earning Date
  • LQDA 05-08-2025
  • EVEX 05-12-2025
  • Dividend Yield
  • LQDA N/A
  • EVEX N/A
  • EPS Growth
  • LQDA N/A
  • EVEX N/A
  • EPS
  • LQDA N/A
  • EVEX N/A
  • Revenue
  • LQDA $14,144,000.00
  • EVEX N/A
  • Revenue This Year
  • LQDA $224.65
  • EVEX N/A
  • Revenue Next Year
  • LQDA $250.54
  • EVEX N/A
  • P/E Ratio
  • LQDA N/A
  • EVEX N/A
  • Revenue Growth
  • LQDA N/A
  • EVEX N/A
  • 52 Week Low
  • LQDA $8.26
  • EVEX $2.33
  • 52 Week High
  • LQDA $19.41
  • EVEX $6.09
  • Technical
  • Relative Strength Index (RSI)
  • LQDA 45.94
  • EVEX 71.05
  • Support Level
  • LQDA $13.94
  • EVEX $4.18
  • Resistance Level
  • LQDA $17.88
  • EVEX $5.60
  • Average True Range (ATR)
  • LQDA 1.40
  • EVEX 0.34
  • MACD
  • LQDA -0.33
  • EVEX 0.12
  • Stochastic Oscillator
  • LQDA 17.92
  • EVEX 89.32

About LQDA Liquidia Corporation

Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also generates revenue from the sale of Treprostinil Injection through an agreement between its subsidiary and the manufacturer.

About EVEX Eve Holding Inc.

Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment , a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.

Share on Social Networks: